Displaying 3441 - 3460 of 4401
FTC Announces Agenda for Petroleum Market Manipulation Rulemaking Workshop
Commission Approves Petition for Proposed Divestiture from Agrium Inc.
Agrium Inc. and UAP Holding Corp ., In the Matter of
The Commission charged that Agrium, Inc.’s $2.65 billion proposed acquisition of UAP Holding Corporation would substantially lessen competition in the market for the retail sale of bulk fertilizer and, in some cases, related services by farm stores, in several local markets in Michigan and Maryland. The Commission’s order requires the divestiture of seven farm stores, five UAP stores in Michigan, and two Agrium locations on the eastern shore of Maryland.
Emerging Health Care Competition and Consumer Issues: Competitive Significance of Health Care Quality Information
FTC Announces Public Workshops for Next Year on Resale Price Maintenance
Hart-Scott-Rodino Premerger Notification Program Back to Basics Workshop
FTC Moves to Block CCSs Proposed Acquisition of Rival Newpark Environmental Services
Commission Approves Final Consent Order in Matter of Fresenius Medical Care AG & Co. KGaA/Daiichi Sankyo Company, Ltd.
Fresenius Medical Care AG & Co. KGaA, et al., In the Matter of
The Commission challenged Fresenius Medical Care’s proposed purchase of an exclusive sublicense for the manufacture and supply of the drug Venofer to US dialysis clinics from Daiichi Sankyo Company. Venofer is an intravenously administered iron sucrose preparation used primarily to treat iron-deficiency anemia in dialysis patients with chronic kidney disease. The agreement would have given Fresenius, the largest operator of dialysis clinics in the country, the ability to artificially inflate its internal costs for Venofer, and effectively increase Medicare reimbursement payments for all buyers of the drug. In order to settle these concerns about anticompetitive self-dealing, the Commission issued a consent order restricting Fresenius from reporting internally inflated Venofer prices by mandating that the current market price for the drug be used in reporting the average selling price to Medicare.
Section 5 of the FTC Act as a Competition Statute
Commission Issues "Excess Consideration" Order in Matter of Rambus, Inc.; FTC Approves Modified Final Consent Order in Matter of Pernod Ricard/V&S Vin & Sprit
Pernod Ricard S.A., In the Matter of
The Commission challenged Pernod Ricard SA’s proposed $9 billion acquisition of V&S Vin & Spirit as harmful to competition among suppliers of “super-premium” vodka. The proposed deal would have merged the two leading brands, Absolut and Stolichnaya, and allowed Pernod to raise prices profitably on both brands. Additionally, the complaint alleges that the markets for cognac, domestic cordials, coffee liqueur, and popular gin would be subject to anticompetitive effects because sensitive pricing and promotion information for Beam Global Brands, a competitor in these product markets, would be available to Pernod after the acquisition as a result of Beam’s joint venture with V&S. The Commission settled the charges by requiring Pernod to divest its distribution interests in Stolichnaya Vodka, and to erect a firewall to prevent the sharing of any competitively sensitive information from Beam Global Brands with Pernod employees.
Dicks Sporting Goods Settles FTC Charges of Illegal Market Allocation
FTC Announces Agenda for Section 5 Public Workshop on October 17, 2008
FTC Intervenes in Hexions Proposed Acquisition of Huntsman Corp.
Commission Approves Final Consent Order in Matter of Negotiated Data Solutions, LLC
Negotiated Data Solutions LLC., In the Matter of
The Commission charged that Negotiated Data Solutions LLC (N-Data) violated Section 5 of the FTC Act by engaging in unfair methods of competition. N-Data acquired patent rights originally held by National Semiconductor Corp. which were included in an IEEE industry standard for autonegotiation technology, which allows Ethernet devices made by different manufacturers to work together. Ethernet is a computer networking standard that is used in nearly every computer sold in the U.S. N-Data reneged on National Semiconductor’s commitment to charge a one-time royalty of $1000 to manufacturers or sellers of products using the IEEE standard, and demanded higher royalties from users. In a consent agreement resolving the charges, N-Data must stop enforcing the patents at issue unless N-Data has first offered a license under the original terms.
Sun Pharmaceutical Industries Ltd., In the Matter of (Taro Pharmaceuticals)
The Commission charged that Sun Pharmaceutical Industries Ltd’s proposed acquisition of Taro Pharmaceuticals Industries, Ltd would substantially reduce competition, likely resulting in higher prices for three distinct generic formulations of the anticonvulsant drug carbamazepine, used widely as an antiepileptic and to prevent and control seizures. The proposed deal would have reduced the number of drug suppliers to a level where the number of competitors has a direct and substantial impact on prices. In order to remedy these concerns, Sun agreed to divest all of its rights and assets needed to develop three generic forms of carbamazepine: 1) immediate-release tablets; 2) chewable tablets; and 3) extended-release tablets.
Displaying 3441 - 3460 of 4401